DRUG RECOMMENDED: Advisers to the European Medicines Agency have endorsed approval of a new anti-clotting drug from Bristol-Myers Squibb and Pfizer for preventing strokes and blood clots in certain high-risk patients.
NEXT STEP: If the European Commission approves Eliquis, the companies could sell it in 29 countries.
THE RACE: Eliquis is one of three drugs in a new class of blood thinners seen as big moneymakers. The other two drugs — Xarelto and Pradaxa — have a head start. They are already on sale in the U.S., which is requiring more data before it will approve Eliquis.